Compare RMBS & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RMBS | CORT |
|---|---|---|
| Founded | 1990 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5B | 9.7B |
| IPO Year | 1997 | 2001 |
| Metric | RMBS | CORT |
|---|---|---|
| Price | $100.28 | $114.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $137.00 | $96.50 |
| AVG Volume (30 Days) | ★ 2.6M | 1.2M |
| Earning Date | 04-27-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.88 | N/A |
| EPS | ★ 0.55 | 0.09 |
| Revenue | $707,630,000.00 | ★ $761,407,000.00 |
| Revenue This Year | $16.01 | $26.08 |
| Revenue Next Year | $16.23 | $26.98 |
| P/E Ratio | ★ $180.58 | $1,228.89 |
| Revenue Growth | ★ 27.13 | 12.79 |
| 52 Week Low | $67.15 | $28.66 |
| 52 Week High | $174.10 | $122.21 |
| Indicator | RMBS | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 48.25 | 64.64 |
| Support Level | $92.62 | $76.41 |
| Resistance Level | $103.92 | $122.21 |
| Average True Range (ATR) | 5.57 | 5.13 |
| MACD | 1.88 | -0.09 |
| Stochastic Oscillator | 83.47 | 75.23 |
Rambus Inc is a semiconductor company providing chips and silicon IP for data-intensive computing systems, focusing on data center and artificial intelligence (AI) infrastructure. The company is at the forefront of enabling the next era of AI-driven computing, addressing challenges of signal and power integrity at increasingly extreme data rates across the data center, edge, and client markets. It offers high-performance memory subsystems, with a balanced and diverse portfolio of products, IP, and patents that maximize performance and security in computationally intensive systems. The company operates in South Korea, Singapore, the United States, and other countries, with the majority of its revenue coming from South Korea.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.